Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers

Journal of Clinical Pharmacology

Volumn 54, Issue 8, 2014, Pages 949-957

  Kakuda, Thomas N ^a   Opsomer, Magda ^b   Timmers, Maarten ^c   Iterbeke, Koen ^c   Van De Casteele, Tom ^b   Hillewaert, Vera ^c   Petrovic, Romana ^b   Hoetelmans, Richard M W ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

bioavailability; cobicistat; darunavir; fixed dose combination; pharmacoenhancer

Indexed keywords

COBICISTAT; DARUNAVIR; RITONAVIR; CARBAMIC ACID DERIVATIVE; CYTOCHROME P450 3A INHIBITOR; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; SULFONAMIDE; THIAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NAUSEA; OPEN STUDY; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN IRRITATION; SOMNOLENCE; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; NORMAL HUMAN; YOUNG ADULT;

ADULT; BIOLOGICAL AVAILABILITY; CARBAMATES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG COMBINATIONS; FEMALE; HEALTHY VOLUNTEERS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES; THIAZOLES; YOUNG ADULT;

EID: 84901063270     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.290     Document Type: Article

References (37)

1. European AIDS Clinical Society (EACS) guidelines,. Version 7. October 2013. http://eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. Accessed March 20, 2014.
2. DHHS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf. Accessed March 20, 2014.
3. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308: 387-402.
4. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012; 13 (Suppl 2): 1-85.
5. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007; 369: 1169-1178.
6. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Syndr. 2007; 46: 24-31.
7. Ortiz R, DeJesus E, Homayoon K, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008; 22: 1389-1397.
8. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009; 23: 1679-1688.
9. Cahn P, Fourie J, Grinstejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011; 25: 929-939.
10. Bánhegyi D, Katlama C, da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012; 10: 171-181.
11. Smith KY, Garcia F, Kumar P, et al. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc. 2012; 104: 366-376.
12. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013; 14: 49-59.
13. Hull MW, Montaner JS,. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011; 43: 375-388.
14. Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A,. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos. 2009; 37: 809-820.
15. Samaras K, Richardson R, Carr A,. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected patients. AIDS. 2010; 24: 1727-1731.
16. Foisy MM, Yakiwchuk EM, Hughes CA,. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008; 42: 1048-1059.
17. Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010; 1: 209-213.
18. Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012; 56: 5409-5413.
19. Shah BM, Schafer JJ, Priano J, Squires KE,. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013; 33: 1107-1116.
20. Lepist EI, Murray BL, Tong L, et al. Effect of Cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2011. Chicago, USA. Abstract A1-1724.
21. Mathias A, Liu HC, Warren D, Sekar V, Kearney BP,. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus RTV. 11th International Workshop on Clinical Pharmacology of HIV Therapy. April 7-9, 2010. Sorrento, Italy. Abstract 28.
22. Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M,. Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient Prefer Adherence. 2012; 6: 427-433.
23. Buscher A, Hartman C, Kallen MA, Giordano TP,. Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Int J STD AIDS. 2012; 23: 351-355.
24. Kauf TL, Davis KL, Earnshaw SR, Davis EA,. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012; 6: 155-164.
25. Juday T, Gupta S, Grimm K, Wagner S, Kim E,. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials. 2011; 12: 71-78.
26. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH,. Fixed dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120: 713-719.
27. Schller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007; 12: 789-796.
28. Mathias A, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010; 87: 322-329.
29. Benincosa LJ, Audet PR, Lundberg D, Zariffa N, Jorkasky DK,. Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects. Biopharm Drug Dispos. 1996; 17: 249-258.
30. Davies NM, Takemoto JK, Brocks DR, Yáñez JA,. Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet. 2010; 49: 351-377.
31. Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD,. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br J Clin Pharmacol. 2010; 69: 475-483.
32. Jackson A, Watson V, Back D, et al. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr. 2011; 58: 450-457.
33. Sekar V, Vanden Abeele C, Van Baelen B, et al. Pharmacokinetic- pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study. 15th Conference on Retroviruses and Opportunistic Infections. February 3-6, 2008. Boston, USA. Poster 769.
34. Sekar V, De La Rosa G, Van de Casteele T, et al. Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial. 10th International Congress on Drug Therapy in HIV Infection. November 7-11, 2010. Glasgow, Scotland. Poster 185.
35. Kakuda TN, Tomaka F, Van De Casteele T, et al. Generalised additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once-daily darunavir/ritonavir 800/100mg treatment in the Phase III trials, ARTEMIS and ODIN. 11th International Congress on Drug Therapy in HIV Infection. November 11-15, 2012. Glasgow, Scotland. Poster P072.
36. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus RTV each with once daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011; 25: 1881-1886.
37. Gallant J, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer for atazanavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients: week 48 results. J Infect Dis. 2013; 208: 32-39.